Related Experiment Video

Updated: Jun 20, 2026

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

Design of a novel MDM2 binding peptide based on the p53 family

Arumugam Madhumalar1, Hui Jun Lee, Christopher J Brown

  • 1Bioinformatics Institute (A-STAR), Singapore, Singapore.

Cell Cycle (Georgetown, Tex.)
|August 29, 2009
PubMed

Insights

Researchers designed a novel peptide inhibitor targeting MDM2, a protein that suppresses tumor suppressor p53. This peptide shows higher affinity and disrupts MDM2-p53 interactions, offering a new therapeutic strategy for cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Structural Biology

Background:

  • p53 is a crucial tumor suppressor protein.
  • MDM2 negatively regulates p53 activity.
  • Disrupting MDM2-p53 interaction is a therapeutic strategy for MDM2-overexpressing tumors.

Purpose of the Study:

  • To understand the structural and energetic basis of MDM2's differential binding to p53 family members.
  • To identify and characterize a novel peptide inhibitor with enhanced affinity for MDM2.
  • To investigate the peptide's dual inhibitory potential against MDMX.

Main Methods:

  • Computational analysis to dissect binding interactions.
  • Peptide design incorporating specific residue arrangements (cationic/anionic, hydrophobic).
  • Fluorescence-based thermal shift assays for affinity validation.

Main Results:

  • A novel peptide was identified with higher affinity for MDM2 than p53.
  • The peptide exhibits increased intrinsic disorder and a strained, yet extensive, binding conformation.
  • Computations indicated dual inhibition of both MDM2 and MDMX.
  • Experimental validation confirmed the computed affinity for MDM2.

Conclusions:

  • A rationally designed peptide inhibitor effectively targets MDM2.
  • The peptide's unique structural features contribute to its high affinity and dual inhibitory activity.
  • This peptide represents a promising therapeutic candidate for cancers associated with MDM2/MDMX overexpression.

More Related Videos

Yeast As a Chassis for Developing Functional Assays to Study Human P5314:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.